Breaking News

Hundreds of incarcerated people are dying of hepatitis C; AbbVie exits major pharma lobbying groups

  

 

Daily Recap

Hundreds of incarcerated people are dying of hep C — even though we have a simple cure

By Nicholas Florko

Nicholas Florko/STAT

More than 1,000 incarcerated people died from hepatitis C-related complications in the six years after a cure hit the market.

Read More

Legal and medical experts say denying hepatitis C care is cruel and unusual punishment, but the courts are still catching up

By Nicholas Florko

Courtesy Fontaine family

Legal and medical experts say denying hepatitis C care is cruel and unusual punishment. But the courts are still catching up.

Read More

STAT+: AbbVie exits major pharmaceutical industry lobbying groups

By Rachel Cohrs and Sarah Owermohle

Ruby Wallau for STAT

The maker of one of the world’s most profitable medicines is exiting the pharma industry’s two major lobbying organizations next year.

Read More

STAT+: Chief health equity officers are growing more common. But experts say companies need to empower them

By Mohana Ravindranath

Adobe

A string of high-profile health companies like Teladoc and CVSHealth have hired their first chief health equity officers this year.

Read More

Listen: Leaky health data, ASH22, & what it takes to get booed by your peers

By Damian Garde and Allison DeAngelis and Adam Feuerstein

STAT's Katie Palmer joins us to explain how telehealth is putting sensitive patient information into the hands of big tech firms.

Read More

STAT+: Biden administration takes aim at Medicare Advantage care denials, misleading ads

By Tara Bannow

Pablo Martinez Monsivais/AP

The Biden administration has big plans for reforming Medicare Advantage in 2024. The biggest targets: care denials and scammy advertisements.

Read More

Thursday, December 15, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments